Clayton JS, Nichole TT, Rolando SS, Julie AW,

Gerard AS. EGFR mutations in malignant pleural

effusions from lung cancer. Current Respiratory

Care Rep 2013, 2:79-87.

Fang W, Chien CL, Szu CY, Aron J, Ziding F,

Gabriel T, Maruja EL, David C, Mao M, Chung

LH, Wu CS, and David TWW. ElectricField

Induced Release and Measurement (EFIRM) can

detect EGFR mutations directly from body fluids

of lung cancer patients. California University

Press 2017, 3:15:131-138.

Fiamma B, Lara F, Maela DG, Giampaolo

F, Alessia DL, Sara M, Patrizia V, Irene C,

Tommaso D’A, Roberta Z, Sandra R, Franco

C, and Antonio M (2019). Effective Assessment

of EGFR Mutation Status inBronchoalveolar

Lavage and Pleural Fluids by Next - Generation

Sequencing.American Association for Cancer

Research, October 16, 2019, 13: 691-699.

Haihong Y, Linbo C, Yalei Z, Hongyu T, Qiuhua

D, Meiling Z, and Xin X. Sensitive Detection

of EGFR Mutations in Cerebrospinal Fluid

from Lung Adenocarcinoma Patients with

Brain Metastases. The Journal of Molecular

Diagnostics, 2014, Vol. 16, No. 5, 23-31.

H Kimura, Y Fujiwara, T Sone, H Kunitoh,

T Tamura, K Kasahara and K Nishio. EGFR

mutation status in tumour - derived DNA from

pleural effusion fluid is a practical basis for

predicting the response to gefitinib. British

Journal of Cancer, 2006, 95, 1390-1395.

Jiang R, Ma C, Lv Y, Mu N, Li J, Wang B, Sun L.

Detected EGFR mutation in cerebrospinal fluid

of lung adenocarcinoma patients with meningeal

metastasis. Open Medecine, 2016, 11:93-96.

Yang J, Lee OJ, Son SM, Woo CG, Jeong Y,

Yang Y, Kwon J, Lee KH, Han HS. EGFR

Mutation Status in Lung Adenocarcinoma -

Associated Malignant Pleural Effusion and

Efficacy of EGFR Tyrosine Kinase Inhibitors;

Cancer Respiratory Treatments, 2008; 50(3):

-916.

Kiyoaki N, Koji T, Toshimi T, Tomoya F, Karin

Y, Hiromi S, Teruhiko Y, Akiko MM, Tatsuhiro

S, Koh F, Yuichiro O, and Yoshihiro M. Detection

of EGFR Mutations in Archived Cytologic

Specimens of Non - Small Cell Lung Cancer

Using High - Resolution Melting Analysis;

American Journal of Clinical Pathology,

,126:608-615.

Maria M B, Ann R H, Steinar S, Lars J, Tommaso

AD, Antonella G, Francesca C, Marco A, Ugo P,

Elin K, Anne - Lise BD, Odd TB and Aslaug H.

Unique microRNA - profiles in EGFR - mutated

lung adenocarcinomas; InternationalJournal

Cancer, 2014, 135, 1812-1821.

Muyun P, Chen C, Alicia H, Malcolm VB and

Fenglei Y. Non-blood circulating tumor DNA

detection in cancer. Oncotarget, 2017, Vol. 8,

(No. 40), 69162-69173.

Olivier C, Anne P, Elvire P, Julien M and

Nicolas G. Molecular biomarkers for lung

adenocarcinoma; European Respiratory Journal,

, 49: 160-734.

Ping Z, Xiaonan W, Min T, Xin N & Lin L (2019).

Detection of EGFR gene mutation status from

pleural effusions and other body fluid specimens

in patients with lung adenocarcinoma. Thoracic

Cancer, 2019,9, 1-11.

Roshni AM, Ryali VSV, B. Shrikar R, Levin

T, Karthik U, Jill K and Mahadev R. Potential

Utility of Liquid Biopsy as a Diagnostic and

Prognostic Tool for the Assessment of Solid

Tumors: Implications in the Precision Oncology.

Journal Clinical Medecine, 2019, 8, 373-382..

Shuanzeng W, David L, Jennifer JDM, Zubair

WB, David BR, and Cindy MG. Using “Residual”

FNA Rinse and Body Fluid Specimens for

Next-Generation Sequencing: An Institutional

Experience. Cancer Cytopathology, May 2016,

-241.

Yi L, Bing L, Xiao - Yan L, Jian - Jie L, Hai -

Feng Q, Chuan - Hao T, Wan - Feng G, Hai - Xu

H, Sha L, Cui - Jing C, Bing L, Hong - Jun G and

Xiao - Qing L. A comparison of ARMS and direct

sequencing for EGFR mutation analysis and

Tyrosine Kinase Inhibitors treatment prediction

in body fluid samples of Non - Small - Cell Lung

Cancer patients. Journal of Experimental &

Clinical Cancer Research 2011, 30:111-119.